Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

A Look At Neurocrine's VMAT-2 Inhibitor As Phase IIb Data Nears

By Jason Napodano, CFA & John Tucker, PhD

Tardive dyskinesia (TD) is a neurological disorder caused by the long-term use of psychiatric drugs (neuroleptics) used in the treatment of schizophrenia. The symptoms of tardive dyskinesia include involuntary and abnormal movements of the jaw, lips, and tongue, including grimacing, sticking out the tongue, and sucking or fish-like movements of the mouth. In some cases, other parts of the body may be affected by rapid, jerking motions (chorea) or slow writhing movements (athetosis). These symptoms cause considerable distress to patients due to the resulting social stigma, and may contribute to poor outcomes such as psychiatric hospitalization by discouraging compliance with treatment. Other medical complications of tardive dyskinesia include difficulty eating, difficulty breathing,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details